Lytix Biopharma is a clinical-stage company committed to developing novel immunotherapy for cancer patients. The aim is to become a leader within immunotherapy of solid tumors.

Lytix Biopharma’s development program focuses on immunological activation of solid tumors such as breast cancer, malignant melanoma, sarcoma, head & neck, and other. The mode of action is to release antigens and reshape the tumor microenvironment and as such turning cold tumors hot.

The strategy is to develop the oncolytic peptides within several tumor type indications, and also explore several therapeutic settings such as combination therapies and T-cell therapies.

For more information, please email us at: post@lytixbiopharma.com


Top 20 shareholders of Lytix Biopharma ASA - as of 1 February 2018
Shareholder Number of shares % of shares
North Murray AS* 2 007 540 16.3
Picasso Kapital AS 1 097 860 8.9
TAJ Holding AS 1 027 210 8.3
CARE Holding AS 773 430 6.3
Norinnova Invest AS 455 060 3.7
Lysnes Invest AS 412 210 3.3
3 T PRODUKTER 389 130 3.2
LMK Venture AB 346 000 2.8
Hopen Invest AS 288 600 2.3
Mikael Lönn 224 900 1.8
Kreftforeningen 218 000 1.8
Per Strand Eiendom AS 196 350 1.6
Rothesay Limited 173 000 1.4
4LB INVEST AS 160 040 1.3
Norinnova Technology Transfer AS 155 790 1.3
John Sigurd Svendsen 152 420 1.2
Sparebank1 Nord-Norge Portefølje AS 151 820 1.2
Jahatt AS 143 640 1.2
Innovasjon Norge AS 133 790 1.1
Øystein Rekdal* 118 630 1.0
Other shareholders 3 709 968 30.1
Total 12 335 388
100.0

*Members of the board and/or management of Lytix Biopharma ASA are represented.

 

* List of insiders within the Board and Management
Lytix Biopharma Board Lytix Biopharma Management
Gert Munthe, Chairman Edwin Klumper, CEO
Kari Grønås, member Håkan Wickholm, CBO
Lena Torlegård, member Øystein Rekdal, Co-founder and CSO
Morten Jurs, member Wenche Marie Olsen, COO
Debasish Roychowdhury, member Torbjørn Furuseth, CFO